1. Home
  2. RMCO vs TNXP Comparison

RMCO vs TNXP Comparison

Compare RMCO & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Royalty Management Holding Corporation

RMCO

Royalty Management Holding Corporation

N/A

Current Price

$2.83

Market Cap

37.9M

Sector

Miscellaneous

ML Signal

N/A

Logo Tonix Pharmaceuticals Holding Corp.

TNXP

Tonix Pharmaceuticals Holding Corp.

HOLD

Current Price

$12.83

Market Cap

199.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RMCO
TNXP
Founded
2021
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Multi-Sector Companies
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
37.9M
199.7M
IPO Year
2021
2008

Fundamental Metrics

Financial Performance
Metric
RMCO
TNXP
Price
$2.83
$12.83
Analyst Decision
Buy
Analyst Count
1
0
Target Price
N/A
N/A
AVG Volume (30 Days)
10.4K
435.4K
Earning Date
05-14-2026
05-11-2026
Dividend Yield
0.35%
N/A
EPS Growth
N/A
91.75
EPS
N/A
N/A
Revenue
$4,949,916.00
$13,107,000.00
Revenue This Year
$209.10
$558.11
Revenue Next Year
$133.33
$38.29
P/E Ratio
N/A
N/A
Revenue Growth
513.30
29.85
52 Week Low
$1.74
$9.40
52 Week High
$5.00
$29.19

Technical Indicators

Market Signals
Indicator
RMCO
TNXP
Relative Strength Index (RSI) 51.99 51.36
Support Level $2.64 $11.98
Resistance Level $3.04 $13.18
Average True Range (ATR) 0.22 0.68
MACD -0.03 -0.08
Stochastic Oscillator 29.52 28.00

Price Performance

Historical Comparison
RMCO
TNXP

About RMCO Royalty Management Holding Corporation

Royalty Management Holding Corp is formed to invest or purchase assets that have near and medium-term income potential to provide RMC with accretive cash flow from which it can reinvest in new assets or expand cash flow from those existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

Share on Social Networks: